JP2010516668A - 抗ウイルス剤のマレイン酸モノ塩及びそれを含有する医薬組成物 - Google Patents
抗ウイルス剤のマレイン酸モノ塩及びそれを含有する医薬組成物 Download PDFInfo
- Publication number
- JP2010516668A JP2010516668A JP2009546316A JP2009546316A JP2010516668A JP 2010516668 A JP2010516668 A JP 2010516668A JP 2009546316 A JP2009546316 A JP 2009546316A JP 2009546316 A JP2009546316 A JP 2009546316A JP 2010516668 A JP2010516668 A JP 2010516668A
- Authority
- JP
- Japan
- Prior art keywords
- maleic acid
- methyl
- free base
- monosalt
- acid monosalt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 title claims abstract description 60
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 title claims abstract description 60
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 title claims abstract description 58
- 239000011976 maleic acid Substances 0.000 title claims abstract description 58
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 10
- 239000003443 antiviral agent Substances 0.000 title description 2
- 150000003839 salts Chemical class 0.000 claims description 36
- 239000007787 solid Substances 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 13
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 6
- 208000036142 Viral infection Diseases 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 4
- VNYVAVVKXIKPBF-BTJKTKAUSA-N 4-[[1-[(2-aminopurin-9-yl)methyl]cyclopropyl]oxymethyl-(2,2-dimethylpropanoyloxymethoxy)phosphoryl]oxy-2,2-dimethylbutanoic acid;(z)-but-2-enedioic acid Chemical compound OC(=O)\C=C/C(O)=O.C1=NC2=CN=C(N)N=C2N1CC1(OCP(=O)(OCOC(=O)C(C)(C)C)OCCC(C)(C)C(O)=O)CC1 VNYVAVVKXIKPBF-BTJKTKAUSA-N 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract description 11
- 229950010765 pivalate Drugs 0.000 abstract description 11
- -1 {1-[(2-amino-9H-purin-9-yl) methyl] cyclopropyl} oxy Chemical group 0.000 abstract description 11
- 239000012458 free base Substances 0.000 description 41
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
- 230000000052 comparative effect Effects 0.000 description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
- 239000000523 sample Substances 0.000 description 12
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 241000700721 Hepatitis B virus Species 0.000 description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 238000000113 differential scanning calorimetry Methods 0.000 description 4
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000011877 solvent mixture Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229940098779 methanesulfonic acid Drugs 0.000 description 3
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- GRTDEERMCBXRMX-UHFFFAOYSA-N 4-[[1-[(2-aminopurin-9-yl)methyl]cyclopropyl]oxymethyl-(2,2-dimethylpropanoyloxymethoxy)phosphoryl]oxy-2,2-dimethylbutanoic acid Chemical compound C1=NC2=CN=C(N)N=C2N1CC1(OCP(=O)(OCOC(=O)C(C)(C)C)OCCC(C)(C)C(O)=O)CC1 GRTDEERMCBXRMX-UHFFFAOYSA-N 0.000 description 1
- HNWMLFCPBQGAAZ-UHFFFAOYSA-N 4-[[1-[(2-aminopurin-9-yl)methyl]cyclopropyl]oxymethyl-(2,2-dimethylpropanoyloxymethoxy)phosphoryl]oxy-2,2-dimethylbutanoic acid;4-methylbenzenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.C1=NC2=CN=C(N)N=C2N1CC1(OCP(=O)(OCOC(=O)C(C)(C)C)OCCC(C)(C)C(O)=O)CC1 HNWMLFCPBQGAAZ-UHFFFAOYSA-N 0.000 description 1
- VGFZLVVVKMKXMF-UHFFFAOYSA-N 4-[[1-[(2-aminopurin-9-yl)methyl]cyclopropyl]oxymethyl-(2,2-dimethylpropanoyloxymethoxy)phosphoryl]oxy-2,2-dimethylbutanoic acid;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=NC2=CN=C(N)N=C2N1CC1(OCP(=O)(OCOC(=O)C(C)(C)C)OCCC(C)(C)C(O)=O)CC1 VGFZLVVVKMKXMF-UHFFFAOYSA-N 0.000 description 1
- SBYKXGKNIRMCEG-UHFFFAOYSA-N 4-[[1-[(2-aminopurin-9-yl)methyl]cyclopropyl]oxymethyl-(2,2-dimethylpropanoyloxymethoxy)phosphoryl]oxy-2,2-dimethylbutanoic acid;naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1.C1=NC2=CN=C(N)N=C2N1CC1(OCP(=O)(OCOC(=O)C(C)(C)C)OCCC(C)(C)C(O)=O)CC1 SBYKXGKNIRMCEG-UHFFFAOYSA-N 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 description 1
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 229940011051 isopropyl acetate Drugs 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- LCCNCVORNKJIRZ-UHFFFAOYSA-N parathion Chemical compound CCOP(=S)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 LCCNCVORNKJIRZ-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
Abstract
【選択図】図3
Description
3−[({1−[(2−アミノ−9H−プリン-9−イル)メチル]シクロプロピル}オキシ)メチル]−8,8−ジメチル−3,7−ジオキソ−2,4,6−トリオキサ−3λ5−ホスファノン−1−イル−ピバレートの遊離塩基及びその塩の含有量を高速液体クロマトグラフィー(HPLC)で測定した。詳細な測定条件は次の通りである。
カラム温度:30℃
流速:1.0mL/分
検出波長:UV309nm
溶離液:A.テトラヒドロフラン/水=3/7
B.テトラヒドロフラン/水=8/2(v/v、勾配溶離)
Mettler Toledo DSC821 systemを用いてDSC曲線を得た。アルミニウムのサンプルパンに試料2〜5mgを入れ、窒素ガス流下で加熱速度10℃/分で25〜250℃の温度範囲にわたって加熱して、熱挙動を検討した。サンプルパンカバーはサンプルパン内部の圧力増加を避けるためにピンホールを有していた。
約20mgの試料を試料ホルダーに充填し、Philips X-ray generator (PW1710) に取り付けた。3〜40゜/2θの範囲で試料の回折パターンを得た。詳細な分析条件は下記の通りである。
Step size:0.03
Scan Mode:step
Voltage/Current:40kV/30mA
2θ/θ反射
Cu-target(Ni-filter)
Source Slit:1.0mm
Detector Slits:0.15mm、1.0mm
3−[({1−[(2−アミノ−9H−プリン−9−イル)メチル]シクロプロピル}オキシ)メチル]−8,8−ジメチル−3,7−ジオキソ−2,4,6−トリオキサ−3λ5−ホスファノン−1−イル−ピバレートの遊離塩基
大韓民国特許登録第0441638号及び国際特許出願公開WO第02/057288号公報に記載された方法によって表題化合物を製造した。
3−[({1−[(2−アミノ−9H−プリン−9−イル)メチル]シクロプロピル}オキシ)メチル]−8,8−ジメチル−3,7−ジオキソ−2,4,6−トリオキサ−3λ5−ホスファノン−1−イル−ピバレートのマレイン酸モノ塩
比較例1で得た遊離塩基100mgを酢酸エチル1mLに溶かした。マレイン酸(1当量)を添加し、混合物を1時間撹拌して固体を生成した。生成された固体をろ過し、酢酸エチルで洗浄し、乾燥して、マレイン酸モノ塩(111.4mg、収率91.3%)を結晶性固体として得た。
示差走査熱量測定:129℃(吸熱:111J/g)
1H NMR(CD3OD):δ8.64(s,1H),8.35(s,1H),6.30(s,2H),5.62(m,4H),4.37(s,2H),4.17(d,2H),1.20(s,18H),0.99(m,4H)
粉末X線回折スペクトル:2θ=5.6,10.0,12.1,13.1,17.5,18.8,20.9,22.8,24.3,25.1及び26.5゜(2θ,+/−0.2)
3−[({1−[(2−アミノ−9H−プリン−9−イル)メチル]シクロプロピル}オキシ)メチル]−8,8−ジメチル−3,7−ジオキソ−2,4,6−トリオキサ−3λ5−ホスファノン−1−イル−ピバレートのマレイン酸三塩
比較例1で得た遊離塩基5gを酢酸エチル50mLに溶かした。マレイン酸(3当量)を添加した。混合物を12時間撹拌し、n−ヘキサン20mLを加えて固体を生成した。生成された固体をろ過し、n−ヘキサンで洗浄し、乾燥して、マレイン酸三塩(6.52g、収率78.6%)を得た。
1H NMR(CD3OD):δ8.70(s,1H),8.46(s,1H),6.31(s,6H),5.62(m,4H),4.38(s,2H),4.17(d,2H),1.20(s,18H),0.99(m,4H)
3−[({1−[(2−アミノ−9H−プリン−9−イル)メチル]シクロプロピル}オキシ)メチル]−8,8−ジメチル−3,7−ジオキソ−2,4,6−トリオキサ−3λ5−ホスファノン−1−イル−ピバレートのp−トルエンスルホン酸モノ塩
比較例1で得た遊離塩基100mgを酢酸エチル1mLに溶かした。p−トルエンスルホン酸(1当量)を添加し、混合物を1時間撹拌して固体を生成した。生成された固体をろ過し、酢酸エチルで洗浄し、乾燥して、p−トルエンスルホン酸モノ塩(106.4mg、収率78.2%)を得た。
1H NMR(CD3OD):δ8.74(s,1H),8.57(s,1H),7.68(d,2H),7.20(d,2H),5.59(m,4H),4.37(s,2H),4.14(d,2H),2.34(s,3H),1.13(s,18H),0.98(m,4H)
3−[({1−[(2−アミノ−9H−プリン−9−イル)メチル]シクロプロピル}オキシ)メチル]−8,8−ジメチル−3,7−ジオキソ−2,4,6−トリオキサ−3λ5−ホスファノン−1−イル−ピバレートのp−トルエンスルホン酸二塩
比較例1で得た遊離塩基5gを酢酸エチル50mLに溶かした。p−トルエンスルホン酸(2当量)を添加し、混合物を1時間撹拌して固体を生成した。生成された固体をろ過し、酢酸エチルで洗浄し、乾燥して、p−トルエンスルホン酸二塩(7.01g、収率81.5%)を得た。
1H NMR(CD3OD):δ8.77(s,1H),8.61(s,1H),7.71(d,4H),7.23(d,4H),5.62(m,4H),4.40(s,2H),4.17(d,2H),2.37(s,6H),1.20(s,18H),0.99(m,4H)
3−[({1−[(2−アミノ−9H−プリン−9−イル)メチル]シクロプロピル}オキシ)メチル]−8,8−ジメチル−3,7−ジオキソ−2,4,6−トリオキサ−3λ5−ホスファノン−1−イル−ピバレートのメタンスルホン酸モノ塩
比較例1で得た遊離塩基100mgを酢酸エチル1mLに溶かした。メタンスルホン酸(1当量)を滴下し、混合物を1時間撹拌して固体を生成した。生成された固体をろ過し、酢酸エチルで洗浄し、乾燥して、メタンスルホン酸モノ塩(95.2mg、収率80.6%)を得た。
1H NMR(CD3OD):δ8.79(s,1H),8.58(s,1H),5.60(m,4H),4.38(s,2H),4.14(d,2H),2.70(s,3H),1.17(s,18H),1.01(m,4H)
3−[({1−[(2−アミノ−9H−プリン−9−イル)メチル]シクロプロピル}オキシ)メチル]−8,8−ジメチル−3,7−ジオキソ−2,4,6−トリオキサ−3λ5−ホスファノン−1−イル−ピバレートのナフタレンスルホン酸モノ塩
比較例1で得た遊離塩基5gを酢酸エチル30mLに溶かした。ナフタレンスルホン酸(1.97g、1当量)を水(5mL)に溶かして、滴下した。混合物を15時間攪拌した後、溶媒を減圧下で完全に除去した。残渣にエタノールとジエチルエーテルを加えて白色結晶を析出した。生成された固体をろ過し、エタノールとジエチルエーテルとの溶媒混合液で洗浄し、乾燥して、ナフタレンスルホン酸モノ塩(6.2g、収率90.0%)を得た。
1H NMR(CD3OD):δ8.48(s,2H),8.44(s,1H),7.95(d,1H),7.83(m,3H),7.50(m,2H),5.63(m,4H),4.23(s,2H),3.95(d,2H),1.18(s,18H),1.01(m,4H)
3−[({1−[(2−アミノ−9H−プリン−9−イル)メチル]シクロプロピル}オキシ)メチル]−8,8−ジメチル−3,7−ジオキソ−2,4,6−トリオキサ−3λ5−ホスファノン−1−イル−ピバレートのエタンスルホン酸モノ塩
比較例1で得た遊離塩基5gを酢酸エチル30mLに溶かした。エタンスルホン酸(1.05g、1当量)を添加して、完全に溶かした。混合物を1時間攪拌した後、溶媒を減圧下で完全に除去した。残渣にエタノール、ジエチルエーテル及びn−ヘキサンを加えて白色結晶を析出した。生成された固体をろ過し、エタノールとジエチルエーテルとの溶媒混合液で洗浄し、乾燥して、エタンスルホン酸モノ塩(5.0g、収率82.8%)を得た。
1H NMR(CDCl3):δ8.60(s,1H),8.51(s,1H),5.63(m,4H),4.32(s,2H),4.00(d,2H),2.92(m,2H),1.29(m,3H),1.19(s,18H),1.01(m,4H)
実施例のマレイン酸モノ塩、比較例1〜5の遊離塩基及び塩のそれぞれ30〜70mgを、ガラス瓶に入れ、40±2℃、及び75±5%RH下で保管した。1、4及び8週間後に、それぞれの試料5mgを採取し、テトラヒドロフラン/水(1/1、v/v)の溶媒混合液に溶かし、HPLCを用いて分析した。その結果を下記表1にまとめた。
実施例のマレイン酸モノ塩、遊離塩基及び比較例6〜7の塩のそれぞれ約5〜6mgをガラス瓶に入れ、60℃で保管した。1又は2、4及び8週間後に、ガラス瓶に入っているそれぞれの試料を採取し、テトラヒドロフラン/水(1/1、v/v)の溶媒混合液に溶かし、HPLCを利用して分析した。その結果を下記表2にまとめた。
実施例のマレイン酸モノ塩及び比較例1の遊離塩基のそれぞれ5〜23mgをガラス瓶に入れた。これに、特定のpH値を有する多様なリン酸緩衝溶液及びリン酸水溶液をそれぞれ500μL加えた。ガラス瓶を水中に入れて25℃の恒温を保持し、混合物を1.5時間撹拌した。ろ過後、ろ液の含有量をHPLCで分析し、その溶液のpHを測定した。測定されたpH値とマレイン酸モノ塩及び遊離塩基の溶解度とを下記表3に示した。
1)細胞培養及び化合物処理
B型肝炎ウイルスを産生する細胞株であるHepG22.2.15(M. A. Shells, et al., Proc. Natl. Acad. Sci. USA 84, 1005 (1987))を10%FBS(ウシ胎仔血清)、1%ABAM(Antibiotic-Antimycotic)、最終濃度400μg/mLのジェネティシン(Geneticin)を含有するDMEM(Dulbecco’s Modified Eagle Media; Life Technologies)中で培養した。細胞が密集するまで培養した後、トリプシンで処理し、96ウェルマイクロプレートに2×104細胞/ウェルの密度で細胞を分注した。24時間後に培地を交換して、比較例1の遊離塩基及び実施例のマレイン酸モノ塩を200μLの培地に最終濃度が50μΜ〜8nMになるように3倍ずつ連続希釈する方法で、2日間隔で、化合物処理を行った。全ての検体について重複して2回実施した。最初の薬物処理から8日後、培養培地を収集し、細胞を100℃で10分加熱して溶解した。DNA増幅反応の阻害物質を最小化するために、培養培地を水で10倍に希釈した。薬物で処理しない対照群の細胞培養培地についても上記と同じ方法で処理した。
上記のように前処理した培養培地6μLをポリメラーゼ/緩衝溶液混合物[10mMのTris−HCl(pH8.3)、50mMのKCl、200μΜのdNTP、200nMのプライマー、200nMのプローブ、3mMのMgCl2、1ユニットのAmpliTaq DNAポリメラーゼ(Applied Biosystems, Foster City, CA)]に加えた。リアルタイムPCR装置(Rotor-Gene 2000 Real-Time Cycler: CORBETT Research)を使用して、95℃で3分反応させた後、95℃で20秒、56℃で30秒、85℃で20秒の反応を45回繰り返した。85℃重合反応で蛍光を検出した。
薬物のCC50値は培地を除去した後、残渣に0.1mg/mLのMTT(Thiazolyl Blue Tetrazolium Bromide: Sigma)100μLを加え、37℃で2時間染色し、DMSO(Dimethyl Sulfoxide: Sigma)100μLを加え、生成された混合物を室温で2時間撹拌して溶かし、540nmで吸光度を測定することによって算定した。
Claims (7)
- 3−[({1−[(2−アミノ−9H−プリン−9−イル)メチル]シクロプロピル}オキシ)メチル]−8,8−ジメチル−3,7−ジオキソ−2,4,6−トリオキサ−3λ5−ホスファノン−1−イル−ピバレートのマレイン酸モノ塩。
- 結晶性固体の形態である、請求項1に記載のマレイン酸モノ塩。
- その粉末X線回折パターンにおいて、2θ=5.6、12.1、17.5及び20.9゜にピークを有している、請求項2に記載のマレイン酸モノ塩。
- その粉末X線回折パターンにおいて、2θ=5.6、10.0、12.1、13.1、17.5、18.8、20.9、22.8、24.3、25.1及び26.5゜にピークを有している、請求項3に記載のマレイン酸モノ塩。
- 請求項1〜4のいずれかに記載のマレイン酸モノ塩;及び薬学的に許容される担体;を含む、ウイルス感染を予防又は治療するための医薬組成物。
- ウイルスがHBVである、請求項5に記載の組成物。
- ウイルスがHIVである、請求項5に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2007-0005269 | 2007-01-17 | ||
KR20070005269 | 2007-01-17 | ||
PCT/KR2008/000194 WO2008088147A1 (en) | 2007-01-17 | 2008-01-11 | Maleic acid monosalt of antiviral agent and pharmaceutical composition containing the same |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010516668A true JP2010516668A (ja) | 2010-05-20 |
JP4980431B2 JP4980431B2 (ja) | 2012-07-18 |
Family
ID=39636116
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009546316A Active JP4980431B2 (ja) | 2007-01-17 | 2008-01-11 | 抗ウイルス剤のマレイン酸モノ塩及びそれを含有する医薬組成物 |
Country Status (17)
Country | Link |
---|---|
US (1) | US20090325904A1 (ja) |
EP (1) | EP2124953A4 (ja) |
JP (1) | JP4980431B2 (ja) |
KR (1) | KR100935904B1 (ja) |
CN (1) | CN101616674B (ja) |
AR (1) | AR064915A1 (ja) |
BR (1) | BRPI0806461B8 (ja) |
CA (1) | CA2673510C (ja) |
CL (1) | CL2008000070A1 (ja) |
CO (1) | CO6210809A2 (ja) |
EA (1) | EA015269B1 (ja) |
MX (1) | MX2009006826A (ja) |
MY (1) | MY163479A (ja) |
TW (1) | TWI384986B (ja) |
UA (1) | UA91655C2 (ja) |
WO (1) | WO2008088147A1 (ja) |
ZA (1) | ZA200904378B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018504891A (ja) * | 2014-12-31 | 2018-02-22 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | リアルタイムPCRによる細胞溶解物からのHBV cccDNA定量化のための新規ハイスループット法 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103665043B (zh) | 2012-08-30 | 2017-11-10 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药及其在医药上的应用 |
CN106977548A (zh) * | 2016-01-19 | 2017-07-25 | 四川海思科制药有限公司 | 倍司福韦复合物及其制备方法和用途 |
KR102623581B1 (ko) * | 2016-07-18 | 2024-01-11 | 일동제약(주) | 항바이러스성 약물의 오로트산염, 이의 제조 방법 및 상기 염을 포함하는 약제학적 조성물 |
KR101899773B1 (ko) * | 2017-03-07 | 2018-09-18 | 일동제약(주) | 베시포비르 디피복실 또는 이의 약제학적 허용되는 염 함유 과립, 상기 과립을 포함하는 약제학적 조성물 및 이의 제조 방법 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004029064A1 (en) * | 2002-09-26 | 2004-04-08 | Lg Life Sciences Ltd. | (+)-trans-isomers of (1-phosphonomethoxy-2-alkylcyclopropyl) methyl nucleoside derivatives, process for the preparation of stereoisomers thereof, and use of antiviral agents thereof |
WO2004029049A1 (ja) * | 2002-09-30 | 2004-04-08 | Yamanouchi Pharmaceutical Co., Ltd. | 2-アシルアミノチアゾール誘導体の新規な塩 |
JP2004518675A (ja) * | 2001-01-19 | 2004-06-24 | エルジー・ライフ・サイエンシーズ・リミテッド | 新規な非環式ヌクレオシドホスホネート誘導体、その塩および合成方法 |
WO2005033098A1 (en) * | 2003-10-02 | 2005-04-14 | Pharmacia & Upjohn Company Llc | Salts and polymorphs of a pyrrole-substituted indolinone compound |
WO2005061488A1 (en) * | 2003-12-24 | 2005-07-07 | Astrazeneca Ab | Maleate salts of a quinazoline derivative useful as an antiangiogenic agent |
WO2007009792A1 (de) * | 2005-07-22 | 2007-01-25 | Grünenthal GmbH | 3-(2-(dimethylamino)methyl-(cyclohex-1-yl))phenol-maleat und dessen kristalline formen |
JP2007045822A (ja) * | 2005-08-08 | 2007-02-22 | Pfizer Inc | Vegf−r阻害剤の塩及び多形体 |
JP2007523180A (ja) * | 2004-02-17 | 2007-08-16 | エルジー・ライフ・サイエンシーズ・リミテッド | Hiv感染治療に有用なヌクレオシドホスホネート誘導体 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2887481A (en) * | 1957-04-29 | 1959-05-19 | Schering Corp | Heterocyclic amides |
US3832460A (en) * | 1971-03-19 | 1974-08-27 | C Kosti | Anesthetic-vasoconstrictor-antihistamine composition for the treatment of hypertrophied oral tissue |
DK161312C (da) * | 1982-03-11 | 1991-12-09 | Pfizer | Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden |
NZ243065A (en) * | 1991-06-13 | 1995-07-26 | Lundbeck & Co As H | Piperidine derivatives and pharmaceutical compositions |
WO1994012497A1 (en) * | 1992-11-20 | 1994-06-09 | Taisho Pharmaceutical Co., Ltd. | Heterocyclic compound |
EP0620222A3 (en) * | 1993-04-14 | 1995-04-12 | Lilly Co Eli | Tetrahydro-beta-carbolines. |
US5795909A (en) * | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
US6624138B1 (en) * | 2001-09-27 | 2003-09-23 | Gp Medical | Drug-loaded biological material chemically treated with genipin |
US7927613B2 (en) * | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
US7444183B2 (en) * | 2003-02-03 | 2008-10-28 | Enteromedics, Inc. | Intraluminal electrode apparatus and method |
US20060106086A1 (en) * | 2004-04-26 | 2006-05-18 | Santiago Ini | Preparation of tegaserod and tegaserod maleate |
KR101033290B1 (ko) * | 2004-07-02 | 2011-05-09 | 주식회사 엘지생명과학 | 다이아이소프로필((1-(하이드록시메틸)-사이클로프로필)옥시)메틸포스포네이트의 새로운 제조 방법 |
CN101304971B (zh) * | 2005-11-08 | 2011-09-07 | 米伦纽姆医药公司 | Xa因子抑制剂n-(5-氯-2-吡啶基)-2-[[4-[(二甲氨基)亚氨基甲基]苯甲酰基]氨基]-5-甲氧基-苯甲酰胺的医药盐和多晶型 |
WO2008033466A2 (en) * | 2006-09-14 | 2008-03-20 | Combinatorx (Singapore) Pre. Ltd. | Compositions and methods for treatment of viral diseases |
EP2078029B1 (en) * | 2006-09-29 | 2014-05-14 | IDENIX Pharmaceuticals, Inc. | Enantiomerically pure phosphoindole as hiv inhibitor |
-
2008
- 2008-01-10 CL CL200800070A patent/CL2008000070A1/es unknown
- 2008-01-10 TW TW097100957A patent/TWI384986B/zh active
- 2008-01-11 UA UAA200907518A patent/UA91655C2/ru unknown
- 2008-01-11 US US12/522,046 patent/US20090325904A1/en not_active Abandoned
- 2008-01-11 CA CA2673510A patent/CA2673510C/en active Active
- 2008-01-11 MY MYPI20092745A patent/MY163479A/en unknown
- 2008-01-11 JP JP2009546316A patent/JP4980431B2/ja active Active
- 2008-01-11 EA EA200970690A patent/EA015269B1/ru unknown
- 2008-01-11 MX MX2009006826A patent/MX2009006826A/es active IP Right Grant
- 2008-01-11 BR BRPI0806461A patent/BRPI0806461B8/pt active IP Right Grant
- 2008-01-11 EP EP08704733A patent/EP2124953A4/en not_active Withdrawn
- 2008-01-11 WO PCT/KR2008/000194 patent/WO2008088147A1/en active Application Filing
- 2008-01-11 CN CN2008800025393A patent/CN101616674B/zh active Active
- 2008-01-14 KR KR1020080004100A patent/KR100935904B1/ko active Protection Beyond IP Right Term
- 2008-01-16 AR ARP080100182A patent/AR064915A1/es not_active Application Discontinuation
-
2009
- 2009-06-23 ZA ZA200904378A patent/ZA200904378B/xx unknown
- 2009-07-17 CO CO09074840A patent/CO6210809A2/es not_active Application Discontinuation
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004518675A (ja) * | 2001-01-19 | 2004-06-24 | エルジー・ライフ・サイエンシーズ・リミテッド | 新規な非環式ヌクレオシドホスホネート誘導体、その塩および合成方法 |
WO2004029064A1 (en) * | 2002-09-26 | 2004-04-08 | Lg Life Sciences Ltd. | (+)-trans-isomers of (1-phosphonomethoxy-2-alkylcyclopropyl) methyl nucleoside derivatives, process for the preparation of stereoisomers thereof, and use of antiviral agents thereof |
WO2004029049A1 (ja) * | 2002-09-30 | 2004-04-08 | Yamanouchi Pharmaceutical Co., Ltd. | 2-アシルアミノチアゾール誘導体の新規な塩 |
WO2005033098A1 (en) * | 2003-10-02 | 2005-04-14 | Pharmacia & Upjohn Company Llc | Salts and polymorphs of a pyrrole-substituted indolinone compound |
WO2005061488A1 (en) * | 2003-12-24 | 2005-07-07 | Astrazeneca Ab | Maleate salts of a quinazoline derivative useful as an antiangiogenic agent |
JP2007523180A (ja) * | 2004-02-17 | 2007-08-16 | エルジー・ライフ・サイエンシーズ・リミテッド | Hiv感染治療に有用なヌクレオシドホスホネート誘導体 |
WO2007009792A1 (de) * | 2005-07-22 | 2007-01-25 | Grünenthal GmbH | 3-(2-(dimethylamino)methyl-(cyclohex-1-yl))phenol-maleat und dessen kristalline formen |
JP2007045822A (ja) * | 2005-08-08 | 2007-02-22 | Pfizer Inc | Vegf−r阻害剤の塩及び多形体 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018504891A (ja) * | 2014-12-31 | 2018-02-22 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | リアルタイムPCRによる細胞溶解物からのHBV cccDNA定量化のための新規ハイスループット法 |
Also Published As
Publication number | Publication date |
---|---|
EA015269B1 (ru) | 2011-06-30 |
AR064915A1 (es) | 2009-05-06 |
MX2009006826A (es) | 2009-07-02 |
EA200970690A1 (ru) | 2009-12-30 |
CL2008000070A1 (es) | 2008-07-25 |
BRPI0806461B1 (pt) | 2019-09-03 |
CN101616674A (zh) | 2009-12-30 |
KR20080067969A (ko) | 2008-07-22 |
TW200836744A (en) | 2008-09-16 |
CO6210809A2 (es) | 2010-10-20 |
ZA200904378B (en) | 2010-05-26 |
US20090325904A1 (en) | 2009-12-31 |
BRPI0806461A2 (pt) | 2011-09-06 |
CA2673510C (en) | 2012-08-21 |
TWI384986B (zh) | 2013-02-11 |
CN101616674B (zh) | 2012-06-13 |
UA91655C2 (ru) | 2010-08-10 |
MY163479A (en) | 2017-09-15 |
WO2008088147A1 (en) | 2008-07-24 |
EP2124953A1 (en) | 2009-12-02 |
CA2673510A1 (en) | 2008-07-24 |
BRPI0806461B8 (pt) | 2021-05-25 |
JP4980431B2 (ja) | 2012-07-18 |
EP2124953A4 (en) | 2011-02-09 |
KR100935904B1 (ko) | 2010-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA3099037A1 (en) | Rip1 inhibitory compounds and methods for making and using the same | |
JP2020518662A (ja) | 化合物の結晶多形、その製造方法及び用途 | |
JP6501773B2 (ja) | 結晶形態のダサチニブの塩 | |
JP4980431B2 (ja) | 抗ウイルス剤のマレイン酸モノ塩及びそれを含有する医薬組成物 | |
WO2016090257A1 (en) | Salts and crystalline forms of 6-acetyl-8-cyclopentyl-5-methyl-2((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d] pyrimidin-7(8h)-one (palbociclib) | |
JP2019526605A (ja) | 置換2−h−ピラゾール誘導体の結晶形、塩型及びその製造方法 | |
TW201829420A (zh) | [(1S)-1-[(2S,4R,5R)-5-(5-胺基-2-酮基-噻唑并[4,5-d]嘧啶-3-基)-4-羥基-四氫呋喃-2-基]丙基]乙酸酯之新穎固態形式 | |
KR20180089904A (ko) | 싸이에노피리미딘 화합물의 결정형 | |
ES2459301T3 (es) | Nuevos polimorfos de lopinavir | |
EP3004103A1 (en) | Crystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1 h-pyrazol-3-ylamino)-6-ethyl-1 -methyl-1,6-dihydroimidazo[4,5 d]fy rrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders | |
US11149013B2 (en) | Crystal form of urate transporter 1 inhibitor and preparation method and use thereof | |
MXPA04005192A (es) | Cristal de derivado de taxano y metodo para preparar el mismo. | |
US20160096838A1 (en) | Crystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1h-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders | |
CN112272667A (zh) | 盐形式 | |
WO2014193881A1 (en) | Crystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1 h-pyrazol-3-ylamino)-6-ethyl-1 -methyl-1,6-dihyrdroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders | |
WO2014193866A1 (en) | Crystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1 h-pyrazol-3-ylamino)-6-ethyl-1 -methyl-1,6-dihydroimidazo[4,5- d]fy rrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders | |
CN114276369B (zh) | 异白叶藤碱类似物、从芦氟沙星到异白叶藤碱类似物的制备方法和应用 | |
CN114276346B (zh) | 异白叶藤碱类似物、从氟罗沙星到异白叶藤碱类似物的制备方法和应用 | |
JP2019500371A (ja) | 置換アミノピラン誘導体の結晶形 | |
WO2022166774A1 (zh) | 3-羟基-5-孕烷-20-酮衍生物的晶型及其制备方法和用途 | |
WO2015109925A1 (zh) | 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途 | |
JP5077232B2 (ja) | ベンゾオキサジアゾール誘導体の結晶 | |
CN113999250A (zh) | 一种以氧氟沙星为原料制备的异白叶藤碱类似物及其制备方法和应用 | |
TW202333694A (zh) | 稠環衍生物的晶型、其製備方法及其應用 | |
CN112851640A (zh) | 嘧啶苯甲酰胺化合物的硫酸盐及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120403 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120418 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150427 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4980431 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D02 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |